Growth & profitability
- Revenue has grown 3.1% per year over the past 5 years.
- Operating margin has contracted, at -5683.7% in the latest year.
Financial health
- Total debt has grown slower than revenue (-81.9% vs 3.1% per year).
VTGN Financials Vistagen Therapeutics, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | $1M | -$70M | 0.0% | -5683.7% | -196.2% | -143.5% | — | — | $31M |
| 2025 | $486000 | -$51M | 0.0% | -11517.1% | -73.0% | -61.0% | — | — | $67M |
| 2024 | $1M | -$29M | 0.0% | -3103.5% | -25.7% | -23.7% | -$26M | — | $119M |
| 2023 | — | -$59M | — | — | -490.5% | -280.9% | -$50M | — | $17M |
| 2022 | $1M | -$48M | 0.0% | -4308.7% | -73.8% | -64.0% | -$45M | — | $68M |
| 2021 | $1M | -$18M | 0.0% | -1646.1% | -19.5% | -16.6% | — | — | $103M |
| 2020 | — | -$21M | — | — | 362.6% | -359.9% | — | — | $1M |
| 2019 | — | -$25M | — | — | -347.5% | -175.5% | — | — | $13M |
| 2018 | — | -$14M | — | — | -207.4% | -127.2% | — | — | $10M |
| 2017 | — | -$10M | — | — | -1665.4% | -276.3% | — | — | $3M |
| 2016 | — | -$47M | — | — | 1586.1% | -4770.7% | — | $58800 | $428500 |
| 2015 | — | -$14M | — | — | 67.6% | -5148.6% | — | $2M | $70000 |
| 2014 | — | -$3M | — | — | 23.2% | -1125.4% | — | $2M | — |
| 2013 | — | -$69M | — | — | 589.6% | -20922.0% | — | — | $20700 |
| 2013 | — | -$69M | — | — | 540.6% | -16981.1% | — | — | $6500 |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $1M | -$13M | 0.0% | -904.3% | -53.2% | -36.5% | — | — | $17M |
| Mar '26 | $465000 | -$16M | 0.0% | -3595.1% | -45.8% | -33.5% | — | — | $31M |
| Dec '25 | $303000 | -$19M | 0.0% | -6450.8% | -37.1% | -29.1% | — | — | $47M |
| Sep '25 | $258000 | -$19M | 0.0% | -7772.5% | -29.3% | -24.0% | — | — | $63M |
| Jun '25 | $244000 | -$15M | 0.0% | -6477.0% | -26.6% | -21.9% | — | — | $49M |
| Mar '25 | -$15000 | -$14M | 0.0% | 96633.3% | -19.4% | -16.2% | — | — | $67M |
| Dec '24 | $234000 | -$14M | 0.0% | -6461.5% | -17.4% | -15.3% | — | — | $75M |
| Sep '24 | $183000 | -$13M | 0.0% | -7774.3% | -13.9% | -12.6% | — | — | $84M |
| Jun '24 | $84000 | -$11M | 0.0% | -14441.7% | -10.2% | -9.5% | — | — | $103M |
| Mar '24 | $197000 | -$10M | 0.0% | -5766.0% | -8.3% | -7.7% | — | — | $119M |
| Dec '23 | $411000 | -$6M | 0.0% | -1918.2% | -5.2% | -4.8% | — | — | $127M |
| Sep '23 | $278000 | -$7M | 0.0% | -2438.8% | -18.5% | -15.6% | — | — | $38M |
| Jun '23 | $177000 | -$7M | 0.0% | -3953.7% | -100.8% | -45.9% | — | — | $10M |
| Mar '23 | — | -$12M | — | — | -101.2% | -58.0% | — | — | $17M |
| Dec '22 | — | -$10M | — | — | -47.2% | -32.9% | — | — | $25M |
| Sep '22 | — | -$17M | — | — | -59.1% | -43.0% | — | — | $35M |
| Jun '22 | $310100 | -$20M | 0.0% | -6376.4% | -42.9% | -33.7% | — | — | $52M |
| Mar '22 | $38900 | -$17M | 0.0% | -42912.6% | -25.8% | -22.4% | — | — | $68M |
| Dec '21 | $357900 | -$11M | 0.0% | -2944.7% | -13.2% | -11.6% | — | — | $84M |
| Sep '21 | $358000 | -$13M | 0.0% | -3575.4% | -15.9% | -12.7% | — | — | $94M |
Valuation over time
How the market has priced VTGN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 200.8× (Apr '24) to 8.6× (Sep '26).
P/S
Frequently asked questions
Is VTGN growing its revenue and profit?
Over the past 5 years, Vistagen Therapeutics, Inc.'s revenue has grown 3.1% per year. These are computed facts, not advice.
How much debt does VTGN have?
As of FY2026, Vistagen Therapeutics, Inc. reported — of total debt against $31M of cash.
What is VTGN's profit margin?
In FY2026, gross margin was —, operating margin -5683.7%, and net margin -5491.9%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.